Cambridge Investment Research Advisors’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.75M | Buy |
8,104
+4,991
| +160% | +$955K | ﹤0.01% | 1793 |
|
|
2026
Q1 | $571K | Sell |
3,113
-4,706
| -60% | -$867K | ﹤0.01% | 2669 |
|
|
2025
Q4 | $1.38M | Buy |
7,819
+3,478
| +80% | +$568K | ﹤0.01% | 1848 |
|
|
2025
Q3 | $608K | Buy |
4,341
+909
| +26% | +$123K | ﹤0.01% | 2486 |
|
|
2025
Q2 | $431K | Sell |
3,432
-396
| -10% | -$49.3K | ﹤0.01% | 2674 |
|
|
2025
Q1 | $524K | Buy |
3,828
+389
| +11% | +$55.6K | ﹤0.01% | 2396 |
|
|
2024
Q4 | $526K | Buy |
3,439
+232
| +7% | +$39.1K | ﹤0.01% | 2386 |
|
|
2024
Q3 | $622K | Sell |
3,207
-172
| -5% | -$36K | ﹤0.01% | 2234 |
|
|
2024
Q2 | $783K | Sell |
3,379
-390
| -10% | -$84.8K | ﹤0.01% | 1943 |
|
|
2024
Q1 | $813K | Sell |
3,769
-1,708
| -31% | -$400K | ﹤0.01% | 1871 |
|
|
2023
Q4 | $1.42M | Sell |
5,477
-282
| -5% | -$69.3K | 0.01% | 1425 |
|
|
2023
Q3 | $1.48M | Sell |
5,759
-9,417
| -62% | -$2.52M | 0.01% | 1328 |
|
|
2023
Q2 | $4.32M | Buy |
15,176
+4,612
| +44% | +$1.37M | 0.02% | 734 |
|
|
2023
Q1 | $2.94M | Buy |
10,564
+5,078
| +93% | +$1.41M | 0.01% | 911 |
|
|
2022
Q4 | $1.52M | Sell |
5,486
-356
| -6% | -$101K | 0.01% | 1249 |
|
|
2022
Q3 | $1.56M | Sell |
5,842
-231
| -4% | -$49.1K | 0.01% | 1184 |
|
|
2022
Q2 | $1.24M | Buy |
6,073
+282
| +5% | +$57.6K | 0.01% | 1324 |
|
|
2022
Q1 | $1.22M | Sell |
5,791
-711
| -11% | -$155K | 0.01% | 1433 |
|
|
2021
Q4 | $1.56M | Sell |
6,502
-650
| -9% | -$167K | 0.01% | 1291 |
|
|
2021
Q3 | $2.02M | Buy |
7,152
+656
| +10% | +$215K | 0.01% | 1089 |
|
|
2021
Q2 | $2.25M | Sell |
6,496
-402
| -6% | -$122K | 0.01% | 1044 |
|
|
2021
Q1 | $1.93M | Buy |
6,898
+710
| +11% | +$191K | 0.01% | 1031 |
|
|
2020
Q4 | $1.51M | Sell |
6,188
-1,085
| -15% | -$280K | 0.01% | 1074 |
|
|
2020
Q3 | $2.06M | Sell |
7,273
-1,030
| -12% | -$287K | 0.01% | 791 |
|
|
2020
Q2 | $2.22M | Buy |
8,303
+1,629
| +24% | +$490K | 0.02% | 724 |
|
|
2020
Q1 | $2.11M | Buy |
6,674
+302
| +5% | +$91.6K | 0.02% | 644 |
|
|
2019
Q4 | $1.89M | Buy |
6,372
+1,454
| +30% | +$403K | 0.01% | 821 |
|
|
2019
Q3 | $1.15M | Sell |
4,918
-765
| -13% | -$178K | 0.01% | 997 |
|
|
2019
Q2 | $1.33M | Sell |
5,683
-450
| -7% | -$104K | 0.01% | 898 |
|
|
2019
Q1 | $1.45M | Buy |
6,133
+87
| +1% | +$27.4K | 0.01% | 853 |
|
|
2018
Q4 | $1.82M | Buy |
6,046
+204
| +3% | +$65.1K | 0.02% | 671 |
|
|
2018
Q3 | $2.06M | Buy |
5,842
+510
| +10% | +$176K | 0.02% | 676 |
|
|
2018
Q2 | $1.55M | Buy |
5,332
+147
| +3% | +$41.3K | 0.02% | 755 |
|
|
2018
Q1 | $1.42M | Sell |
5,185
-600
| -10% | -$186K | 0.02% | 766 |
|
|
2017
Q4 | $1.84M | Sell |
5,785
-163
| -3% | -$52.3K | 0.02% | 619 |
|
|
2017
Q3 | $1.86M | Buy |
5,948
+520
| +10% | +$154K | 0.03% | 561 |
|
|
2017
Q2 | $1.47M | Sell |
5,428
-32
| -0.6% | -$8.46K | 0.02% | 633 |
|
|
2017
Q1 | $1.49M | Buy |
5,460
+125
| +2% | +$35.3K | 0.03% | 560 |
|
|
2016
Q4 | $1.51M | Sell |
5,335
-26
| -0.5% | -$7.71K | 0.03% | 519 |
|
|
2016
Q3 | $1.68M | Buy |
5,361
+5
| +0.1% | +$1.48K | 0.03% | 480 |
|
|
2016
Q2 | $1.29M | Buy |
5,356
+404
| +8% | +$106K | 0.03% | 496 |
|
|
2016
Q1 | $1.29M | Buy |
4,952
+495
| +11% | +$131K | 0.03% | 476 |
|
|
2015
Q4 | $1.36M | Buy |
4,457
+586
| +15% | +$168K | 0.03% | 456 |
|
|
2015
Q3 | $1.13M | Buy |
3,871
+179
| +5% | +$59.1K | 0.03% | 445 |
|
|
2015
Q2 | $1.49M | Buy |
3,692
+198
| +6% | +$79.5K | 0.04% | 383 |
|
|
2015
Q1 | $1.48M | Sell |
3,494
-1,265
| -27% | -$499K | 0.04% | 375 |
|
|
2014
Q4 | $1.61M | Buy |
4,759
+1,759
| +59% | +$569K | 0.05% | 340 |
|
|
2014
Q3 | $992K | Buy |
3,000
+42
| +1% | +$13.8K | 0.03% | 527 |
|
|
2014
Q2 | $933K | Buy |
2,958
+232
| +9% | +$69.8K | 0.03% | 479 |
|
|
2014
Q1 | $834K | Buy |
2,726
+699
| +34% | +$222K | 0.03% | 486 |
|
|
2013
Q4 | $567K | Sell |
2,027
-102
| -5% | -$26.4K | 0.02% | 602 |
|
|
2013
Q3 | $513K | Sell |
2,129
-167
| -7% | -$37.4K | 0.02% | 617 |
|
|
2013
Q2 | $494K | Buy |
+2,296
| New | +$491K | 0.03% | 554 |
|
Other funds holding BIIB
Cambridge Investment Research Advisors's BIIB Position: Q2 2026 in Review
Cambridge Investment Research Advisors increased its Biogen (BIIB) stake by 160% in Q2 2026, buying an estimated $955K and bringing the position to 8,104 shares worth $1.75M. The position accounts for ﹤0.01% of the portfolio, ranked #1793.
Cambridge Investment Research Advisors first reported a position in BIIB in Q2 2013 and has held it in 53 quarters since. The position peaked at $4.32M in Q2 2023. 1,036 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.
- Cambridge Investment Research Advisors held 8,104 shares of Biogen worth $1.75M as of Q2 2026.
- Cambridge Investment Research Advisors bought 4,991 Biogen shares in Q2 2026, an estimated $955K.
- Biogen made up ﹤0.01% of Cambridge Investment Research Advisors's portfolio in Q2 2026, its #1793 holding.
- Cambridge Investment Research Advisors first reported a position in Biogen in Q2 2013 and has held it in 53 quarters since.
- Cambridge Investment Research Advisors's Biogen position peaked at $4.32M in Q2 2023.
- 1,036 funds tracked by Wall St. Rank held Biogen as of Q2 2026.
Based on Cambridge Investment Research Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.